The histone deacetylase inhibitor MS-275 induces p21WAF1/Cip1 expression in human Hep3B hepatoma cells

Drug Development Research

Volumn 68, Issue 2, 2007, Pages 61-70

  Zhang, Haiyuan ^a   Chen, Ping ^b   Bai, Shujun ^b   Huang, Canhua ^b  

^a YANGTZE UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Cancer chemotherapy; ChIP assay; Hepatoma cells; Histone deacetylase inhibitor; MS 275; p21WAF1 Cip1

Indexed keywords

BENZAMIDE DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; MYC PROTEIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PROTEIN P27; PROTEIN P300; RNA POLYMERASE II;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; HEPATOMA CELL; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION;

EID: 34547642383     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20167     Document Type: Article

References (33)

1. Bernstein BE, Humphrey EL, Erlich RL, Schneider R, Bouman P, Liu JS, Kouzarides T, Schreiber SL. 2002. Methylation of histone H3 Lys 4 in coding regions of active genes. Proc Natl Acad Sci USA 99:8695-8700.
2. Chiba T, Yokosuka O, Arai M, Tada M, Fukai K, Imazeki F, Kato M, Seki N, Saisho H. 2004. Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol 41:436-445.
3. Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD, Coffey RJ. 1997. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat Med 3:1233-1241.
4. Gabrielli BG, Johnstone RW, Saunders NA. 2002. Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress. Curr Cancer Drug Targets 2:337-353.
5. Gartel AL. 2005a. Lost in transcription: p21 repression, mechanisms and consequences. Cancer Res 65:3980-3985.
6. Gartel AL. 2005b. The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk Res 29:1237123-1237128.
7. WAF1/CIP1 gene. Exp Cell Res 246:280-289.
8. Gartel AL, Tyner AL. 2002. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1:639-649.
9. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. 2003. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors triehostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278:12579-12589.
10. Hess-Stumpp H. 2005. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 84:109-121.
11. Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, Beppu T. 1994. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 214:189-197.
12. Hsu SL, Chen MC, Chou YH, Hwang GY, Yin SC. 1999. Induction of p21(CIP1/Waf1) and activation of p34(cdc2) involved in retinoic acid-induced apoptosis in human hepatoma Hep3B cells. Exp Cell Res 248:87-96.
13. Jaboin J, Hamidi WJ, Khanna H, Kim C, Robey CJ, Bates SE, Thiele CJ. 2002. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 62:6108-6115.
14. Kim WH, Kang KH, Kim MY, Choi KH. 2000. Induction of p53independent p21 during ceramide-induced G1 arrest in human hepatocarcinoma cells. Biochim Biol Cell 78:127-135.
15. Kramer OH, Gottlicher M, Heinzel T. 2001. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12:294-300.
16. Lee BI, Park SH, Kim JW, Sausville EA, Kim HT, Nakanishi O, Trepel JB, Kim SJ. 2001. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor β type II receptor expression in human breast cancer cells. Cancer Res 61:931-934.
17. WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem Biophys Res Commun 324:860-867.
18. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. 1997. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:251-260.
19. Marks PA, Richon VM, Rifkind RA. 2000. Histone deacetylase inhibitors: Induces of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216.
20. Marks PA, Richon VM, Breslow R, Rifkind RA. 2001. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13:477-483.
21. Mei S, Ho AD, Mahlknecht U. 2004. Role of histone deacetylase inhibitors the treatment of cancer. Int J Cancer 25:1509-1519.
22. Niculescu AB, Chen X, Smeets M, Hengst L, Prives C, Reed SI. 1998. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18:629-643.
23. Nilsson JA, Cleveland JL. 2003. Myc pathways provoking cell suicide and cancer. Oncogene 22:9007-9021.
24. Noh EJ, Lee JS. 2003. Functional interplay between modulation of histone deacetylase activity and its regulatory role in G2-M transition. Biochem Biophys Res Commun 310:267-273.
25. Park SH, Lee SR, Kim BC, Cho EA, Patel SP, Kang HB, Sausville EA, Nakanishi O, Trepel JB, Lee BI, Kim SJ. 2002. Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. J Biol Chem 277:5168-5174.
26. Ryu JK, Lee WJ, Lee KH, Hwang JH, Kim YT, Yoon YB, Kim CY. 2006. SK-7041, a new histone deacetylase inhibitor, induces G(2)-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett 237:143-154.
27. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O. 1999. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96:4592-4597.
28. Seoane J, Le HV, Massague J. 2002. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419:729-734.
29. Strahl BD, Strahl BD, Allis CD. 2000. The language of covalent histone modifications. Nature 403:41-45.
30. Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, Yamashita T, Nakanishi O. 1999. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 42:3001-3003.
31. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA. 2005. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:673-678.
32. Wade PA, Pruss D, Wolffe AP. 1997. Histone acetylation: chromatin in action. Trends Biochem Sci 22:128-132.
33. Wolffe AP, Guschin D. 2000. Review: chromatin structural features and targets that regulate transcription. J Struct Biol 2000 129:102-129:122.